WW9: THE USE OF MULTI-ATTRIBUTE ANALYSIS AND PAIR-WISE COMPARISONS FOR GROUP DECISION-MAKING  by Hess, GP & Forman, E
192 Abstracts
WW9
THE USE OF MULTI-ATTRIBUTE ANALYSIS AND 
PAIR-WISE COMPARISONS FOR GROUP 
DECISION-MAKING
Hess GP1, Forman E2
1CareScience, Philadelphia, PA, USA; 2George Washington 
University, Washington, DC, USA
OBJECTIVES: Decision-making is a process of assessing
alternatives and their attributes versus an objective(s),
trading-off various advantages and disadvantages, and
ultimately synthesizing the information to culminate at a
central point: a decision. The aim of the workshop is to
outline a systematic process for group decision-making.
A formulary decision incorporating clinical, economic
and humanistic data from the perspective of a hospital
committee will be used as an illustration.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers who are involved in creating group decision-analytic
models and systems, and stakeholders involved in formu-
lary selection.
A key issue in pharmaceutical research is the development
and use of applied approaches to help decision-makers
synthesize various pieces of information and arrive at a
decision. Decision-making is often difficult because trade-
offs must be made among competing objectives and pri-
orities. In order to make tradeoffs, we must be able to
evaluate and measure each aspect of the decision—some
quantitative, some qualitative, some very important, and
some not so important. Uncertainties and competing in-
terest groups also add to the complexity of decision-mak-
ing. The ability to make effective decisions in the face of
complexity can be significantly increased by a systematic
process incorporating multiple attributes (economics, clin-
ical outcomes, etc.) and pairwise comparisons (A vs. B, B
vs. C, A vs. C). The session will describe a systematic ap-
proach and provide an interactive illustration for con-
struction of a decision-model based on a process devel-
oped by mathematicians at the Wharton School of the
University of Pennsylvania. A model will be developed
for the formulary selection of cholesterol lowering statins
from a hospital P&T perspective, considering economic,
clinical and humanistic outcomes, with participation
from the audience including handheld key pads for input.
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MULTINATIONAL ECONOMIC STUDIES: 
LESSONS LEARNED FROM TRIAL-BASED AND 
MODELLING STUDIES
Drummond MF1, Grima D2
1University of York, Heslington, York, UK; 2Innovus Research 
Inc, Burlington, ON, Canada
WORKSHOP OBJECTIVE: The interest in multinational
health economic studies has grown with the number of
countries requiring economic data on new pharmaceuti-
cals. The workshop will explore and illustrate challenges
in the conduct of international studies using examples
from the presenters’ research while providing an oppor-
tunity for participants to share their experiences.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers who are involved in the design, execution or commis-
sion of multinational health economic studies.
As health care expenditures have risen, so too has scrutiny
over the economic value of new pharmacological inter-
ventions. Many countries now require that the cost-
effectiveness of new agents be addressed in formal analy-
ses as part of the regulatory approval process. Given
these widespread requirements, there has been a growing
interest in undertaking multinational health economic
studies that can be used as the basis for submissions in
multiple countries. Two main strategies to provide health
economic data include: creation of decision analytic mod-
els that utilize existing clinical, epidemiological and cost
data, and collection of economic data alongside multina-
tional clinical trials. Each raises methodological chal-
lenges, which will be discussed using examples from stud-
ies in rheumatology, vaccination, stroke, and cardiovascular
disease. For example, in modeling studies, how does one
accommodate local clinical practice patterns? In trial-
based studies, how does one decide whether economic
data can be pooled or not? Multinational studies also
raise a number of practical issues, such as the involve-
ment of a cross-section of international experts to avoid
the introduction of country-specific biases, creation of
buy-in among national offices and decision experts, avail-
ability of resource use and unit cost data, and require-
ments for a multinational publication strategy. These is-
sues will also be discussed.
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USING MARKOV DECISION MODELS TO 
DEVELOP OPTIMAL TREATMENT PATHWAYS: 
AN ILLUSTRATION
Bala MV1, Mauskopf JA2
1Centocor, Inc, Malvern, PA, USA; 2Research Triangle Institute, 
Research Triangle Park, NC, USA
OBJECTIVES: The objective of this workshop will be to
develop skills in the use of Markov decision models to
develop treatment pathways that are optimal from a
pharmacoeconomic perspective.
PARTICIPANTS WHO WOULD BENEFIT: Analysts or
decision-makers involved in the conduct or evaluation of
pharmacoeconomic studies.
Cost-effectiveness analysis of an intervention for a
chronic condition requires estimates of cost and efficacy
over the rest of the patient’s life time. However efficacy
estimates are commonly derived from clinical trials with
limited duration of follow-up. This creates the need for
modeling to estimate cost and efficacy beyond the follow-
up period. Markov modeling is the most commonly used
modeling technique to perform this estimation. However,
